Stock Taper
SCREENER COMPARE ANY 2 STOCKS
AVBP
ARRIVENT BIOPHARMA, INC.
NASDAQ
$30.95
▼ DOWN 0.26% (-0.08)

KEY STATISTICS

Market Cap$1.45 B
52w High$35.83
52w Low$17.00
Dividend Yield—
Frequency—
P/E-8.92
Volume182.37K
Shares Out.46.57M

COMPANY

LEADERSHIP

Zhengbin Yao
CHIEF EXECUTIVE
Zhengbin Yao

COMPENSATION 2026

Salary$596,667
Stock Awards$0
Incentive Plan Pay$358,000
All Other Comp.$14,000
Total$9,374,153

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 26, 2024
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
77

PRICE TARGET

Target High$47.00
Target Low$45.00
Target Median$46.00
Target Consensus$46.00

UPCOMING EARNINGS

DateNov 16, 2026
DayMonday
Rev. Est.$800.00K
NOV
16
MON

PRICE

$30.95 ▼ DOWN 0.26% (−$0.08)
$30.75$31.00$31.259:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM30.95

About ArriVent BioPharma, Inc.

https://arrivent.com ↗

ArriVent BioPharma, a clinical-stage biopharma based in Pennsylvania, develops targeted cancer therapies like Furmonertinib for NSCLC and solid tumors, with strategic collaborations and a focus on unmet medical needs.

INDUSTRY

Biotechnology

A PRODUCT ARRIVENT BIOPHARMA, INC. IS KNOWN FOR

Firmonertinib
Firmonertinib

Firmonertinib is an oral, brain-penetrant EGFR inhibitor in Phase 3 trials for NSCLC with specific mutations, and ArriVent BioPharma's primary focus is on its success.

COMPETITORS

COMPETITOR
CGEM COMPARE
NU NUVL COMPARE
SMMT COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
118
LISTED HERE
21
RANKED BY POSITION SIZE
VTI
0.00% · 1.3M
XSU.TO
0.04% · 969.5K
XBI
0.25% · 934.0K
SCHA
0.02% · 162.6K
FESM
0.07% · 138.8K
SBIO
0.80% · 64.2K
DFMC
0.02% · 60.8K
XRSU.L
0.04% · 33.8K
LABU
0.17% · 31.2K
CANC
0.31% · 21.9K
OP
OPTZ
0.22% · 19.3K
RSSL
0.04% · 18.2K
BBC
0.63% · 10.3K
PRFZ
0.01% · 9.9K
GSSC
0.02% · 6.5K
BIB
0.05% · 1.7K
AVSC
0.00% · 1.5K
VETS
0.06% · 569
KBFR
0.12% · 530
USUE.DE
0.00% · 123
RESM
0.03% · 65

INSTITUTIONAL OWNERSHIP

SHARES OWNED
73.93%
HOLDERS
188
TOP 12 OF 188 · RANKED BY POSITION SIZE
Suvretta Capital Management, LLC
4.5M sh · $156.87M
Hhlr Advisors, Ltd.
4.5M sh · $82.74M
Infinitum Asset Management, LLC
4.4M sh · $154.19M
Fmr LLC
3.7M sh · $74.52M
Blackrock, Inc.
3.3M sh · $112.92M
Orbimed Advisors LLC
3.0M sh · $60.91M
Vanguard Group Inc
2.0M sh · $37.44M
Octagon Capital Advisors LP
2.0M sh · $68.47M
Novo Holdings A/S
1.9M sh · $44.81M
Sofinnova Investments, Inc.
1.7M sh · $58.95M
State Street Corp
1.7M sh · $58.81M
Vivo Capital, LLC
1.7M sh · $58.44M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity5
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR
Parsey Merdad
Purchase · 13.6K shares
2026-06-18
★
DIRECTOR
Hohneker John
Purchase · 13.6K shares
2026-06-18
★
DIRECTOR
Nolet Chris
Purchase · 13.6K shares
2026-06-18
★
DIRECTOR
Peterson Kristine
Purchase · 13.6K shares
2026-06-18

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 6
OUTPERFORM 1
7 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY BTIG BUY Citigroup BUY Guggenheim BUY Truist Securities BUY B. Riley Securities BUY Oppenheimer OUTPERFORM

SECTORS PEERS

PEERPRICE
ERAS$16.14COMPARE
IOVA$8.69COMPARE
MBX$61.39COMPARE
MGTX$13.86COMPARE
REPL$15.03COMPARE
VALN$6.99COMPARE
ARVN$9.41COMPARE
DNA$6.91COMPARE